BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33478888)

  • 21. Cellular Therapy in NSCLC: Between Myth and Reality.
    Imbimbo M; Wetterwald L; Friedlaender A; Parikh K; Addeo A
    Curr Oncol Rep; 2023 Oct; 25(10):1161-1174. PubMed ID: 37646900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive Immunotherapy beyond CAR T-Cells.
    Titov A; Zmievskaya E; Ganeeva I; Valiullina A; Petukhov A; Rakhmatullina A; Miftakhova R; Fainshtein M; Rizvanov A; Bulatov E
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR T cell therapy: A new era for cancer treatment (Review).
    Mohanty R; Chowdhury CR; Arega S; Sen P; Ganguly P; Ganguly N
    Oncol Rep; 2019 Dec; 42(6):2183-2195. PubMed ID: 31578576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic T cell receptor-based lymphocytes for cancer therapy.
    Getts D; Hofmeister R; Quintás-Cardama A
    Adv Drug Deliv Rev; 2019 Feb; 141():47-54. PubMed ID: 30981835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
    Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
    J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
    Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
    Front Immunol; 2017; 8():1850. PubMed ID: 29312333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive cell therapy in multiple Myeloma.
    Vallet S; Pecherstorfer M; Podar K
    Expert Opin Biol Ther; 2017 Dec; 17(12):1511-1522. PubMed ID: 28857616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
    Perez C; Gruber I; Arber C
    Front Immunol; 2020; 11():583716. PubMed ID: 33262761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospects and challenges for use of CAR T cell therapies in solid tumors.
    Ramakrishna S; Barsan V; Mackall C
    Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
    Miliotou AN; Papadopoulou LC
    Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
    Morgan MA; Schambach A
    Front Immunol; 2018; 9():2493. PubMed ID: 30420856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors].
    Ikeda H
    Rinsho Ketsueki; 2019; 60(6):716-722. PubMed ID: 31281165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.